Your browser doesn't support javascript.
loading
Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue.
Medlow, Paul Wallace; Steele, Christopher James; McCavigan, Andrena Marie; Reardon, Wesley; Brown, Christopher Michael; Lambe, Shauna May; Ishiy, Felipe Augusto Andre; Walker, Steven Michael; Logan, Gemma Elizabeth; Raji, Olaide Yaqeen; Berge, Viktor; Katz, Betina; Kay, Elaine Williamson; Sheehan, Katherine; Watson, Ronald William; Harkin, Denis Paul; Kennedy, Richard Darragh; Knight, Laura Anne.
Afiliación
  • Medlow PW; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Steele CJ; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • McCavigan AM; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Reardon W; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Brown CM; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Lambe SM; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Ishiy FAA; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Walker SM; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Logan GE; Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, UK.
  • Raji OY; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Berge V; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Katz B; Department of Urology, Oslo University Hospital, Oslo, Norway.
  • Kay EW; Department of Pathology, Oslo University Hospital, Oslo, Norway.
  • Sheehan K; Department of Pathology, RCSI, Beaumont Hospital, Dublin, Ireland.
  • Watson RW; Department of Pathology, RCSI, Beaumont Hospital, Dublin, Ireland.
  • Harkin DP; UCD School of Medicine, Conway Institute, University College Dublin, Belfield, Dublin, Ireland.
  • Kennedy RD; Almac Diagnostics Ltd., Craigavon, Northern Ireland, UK.
  • Knight LA; Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, UK.
BMC Med Genomics ; 11(1): 125, 2018 Dec 27.
Article en En | MEDLINE | ID: mdl-30591067
BACKGROUND: There is a clear need for assays that can predict the risk of metastatic prostate cancer following curative procedures. Importantly these assays must be analytically robust in order to provide quality data for important clinical decisions. DNA microarray based gene expression assays measure several analytes simultaneously and can present specific challenges to analytical validation. This study describes the analytical validation of one such assay designed to predict metastatic recurrence in prostate cancer using primary formalin fixed paraffin embedded tumour material. METHODS: Accuracy was evaluated with a method comparison study between the assay development platform (Prostate Disease Specific Array) and an alternative platform (Xcel™ microarray) using 50 formalin-fixed, paraffin-embedded prostate cancer patient samples. An additional 70 samples were used to establish the assay reportable range. Determination of assay precision and sensitivity was performed on multiple technical replicates of three prostate cancer samples across multiple variables (operators, days, runs, reagent lots, and equipment) and RNA/cDNA inputs respectively using the appropriate linear mixed model. RESULTS: The overall agreement between the development and alternative platform was 94.7% (95% confidence interval, 86.9-98.5%). The reportable range was determined to be 0.150 to 1.107 for core needle biopsy samples and - 0.214 to 0.844 for radical prostatectomy samples. From the precision study, the standard deviations for assay repeatability and reproducibility were 0.032 and 0.040 respectively. The sensitivity study demonstrated that a total RNA input and cDNA input of 50 ng and 3.5 µg respectively was conservative. CONCLUSION: The Metastatic Assay was found to be highly reproducible and precise. In conclusion the studies demonstrated an acceptable analytical performance for the assay and support its potential use in the clinic.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Regulación Neoplásica de la Expresión Génica / Perfilación de la Expresión Génica Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: BMC Med Genomics Asunto de la revista: GENETICA MEDICA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Regulación Neoplásica de la Expresión Génica / Perfilación de la Expresión Génica Tipo de estudio: Prognostic_studies Límite: Humans / Male Idioma: En Revista: BMC Med Genomics Asunto de la revista: GENETICA MEDICA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido